Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 2/20 | 0.37 |
| ▸ | STK4 | Q13043 | 7/20 | 0.36 |
| ▸ | STK3 | Q13188 | 7/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295700 | 0.83 | SRC (0.42) | RIPK2ADKSTK4STK3LRRK2 | |
| SCHEMBL30295703 | 0.79 | STK4 (0.45) | RIPK2STK4STK3LRRK2LMNA | |
| SCHEMBL30295902 | 0.79 | STK4 (0.44) | RIPK2STK4STK3LRRK2LMNA | |
| SCHEMBL30295809 | 0.79 | LMNA (0.46) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL30295816 | 0.77 | LMNA (0.47) | ADKSTK4STK3LRRK2LMNA | |
| SCHEMBL30295741 | 0.76 | ADK (0.47) | ADKSTK4STK3LRRK2SRC | |
| SCHEMBL30295769 | 0.76 | STK4 (0.53) | RIPK2ADKSTK4STK3LRRK2 | |
| SCHEMBL30295820 | 0.75 | LMNA (0.49) | ADKSTK4STK3LRRK2SRC | |
| SCHEMBL30295914 | 0.75 | STK4 (0.54) | ADKSTK4STK3LRRK2SRC | |
| SCHEMBL30295785 | 0.75 | ADK (0.47) | ADKSTK4STK3LRRK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | RIPK2 96/4885ADK 268/4885STK4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.